CO6140062A2 - Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas - Google Patents
Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosasInfo
- Publication number
- CO6140062A2 CO6140062A2 CO09135218A CO09135218A CO6140062A2 CO 6140062 A2 CO6140062 A2 CO 6140062A2 CO 09135218 A CO09135218 A CO 09135218A CO 09135218 A CO09135218 A CO 09135218A CO 6140062 A2 CO6140062 A2 CO 6140062A2
- Authority
- CO
- Colombia
- Prior art keywords
- cdmab
- monoclonal antibody
- ovary
- prostate
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un método de reducción de un tumor pancreático, de seno, próstata, ovario o colon humano en un mamífero, caracterizado porque el tumor pancreático, de seno, próstata, ovario o colon humano expresa al menos un epítopo de un antígeno que se une específicamente al anticuerpo monoclonal aislado producido por la línea de células de hibridoma depositada en la IDAC con el número de registro 141205-05 o un CDMAB del mismo, CDMAB con capacidad para inhibir competitivamente la unión del anticuerpo rnonoclonal aislado a su antígeno objetivo, y que comprende administrar al mamífero el anticuerpo monoclonal o CDMAB del mismo en una cantidad efectiva para dar como resultado una reducción de la carga tumoral de páncreas, seno, próstata, ovario o colon del mamífero.2.- El método de conformidad con la reivindicación 1, caracterizado porque el anticuerpo monoclonal aislado es conjugado a una porción citotóxica. 3.- El método de conformidad con la reivindicación 2, caracterizado porqué la porción citotóxica es un isótopo radioactivo.4.- El método de conformidad con la reivindicación 1, caracterizado porque el anticuerpo monoclonal aislado o CDMAB del mismo activa complemento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/807,837 US20080131428A1 (en) | 2006-02-24 | 2007-05-30 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6140062A2 true CO6140062A2 (es) | 2010-03-19 |
Family
ID=39476049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09135218A CO6140062A2 (es) | 2007-05-30 | 2009-11-26 | Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080131428A1 (es) |
| EP (1) | EP2155791A4 (es) |
| JP (1) | JP2010528056A (es) |
| KR (1) | KR20100003366A (es) |
| CN (1) | CN101679526A (es) |
| AU (1) | AU2008255528A1 (es) |
| CA (1) | CA2687586A1 (es) |
| CO (1) | CO6140062A2 (es) |
| CR (1) | CR11127A (es) |
| EC (1) | ECSP099770A (es) |
| IL (1) | IL202092A0 (es) |
| MA (1) | MA31393B1 (es) |
| MX (1) | MX2009012732A (es) |
| WO (1) | WO2008144891A1 (es) |
| ZA (1) | ZA200908346B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| AU2002246632B2 (en) * | 2000-12-08 | 2007-04-05 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
| KR101459159B1 (ko) * | 2006-01-12 | 2014-11-12 | 알렉시온 파마슈티칼스, 인코포레이티드 | Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도 |
| AU2007261247A1 (en) * | 2006-06-22 | 2007-12-27 | Vaccinex, Inc. | Anti-C35 antibodies for treating cancer |
| CA2672468A1 (en) * | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| CA2694121C (en) * | 2007-07-25 | 2016-06-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| AU2009339664B2 (en) * | 2009-02-05 | 2014-12-04 | Oncoxx Biotech S.R.L. | Anti-Trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors |
| SG185583A1 (en) * | 2010-05-17 | 2012-12-28 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
| JPWO2011155579A1 (ja) * | 2010-06-10 | 2013-08-15 | 北海道公立大学法人 札幌医科大学 | 抗Ｔｒｏｐ−２抗体 |
| CA2807942C (en) | 2010-08-10 | 2021-07-27 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| AU2012290957B2 (en) * | 2011-08-04 | 2017-04-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| JP5936702B2 (ja) * | 2011-11-11 | 2016-06-22 | ライナット ニューロサイエンス コーポレイション | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
| US9427464B2 (en) * | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| CN104159914A (zh) * | 2011-12-19 | 2014-11-19 | 爱尔兰詹森研发公司 | Hiv膜融合抑制剂 |
| ITCH20120008A1 (it) * | 2012-05-16 | 2013-11-17 | Saverio Alberti | Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate |
| CA2933666C (en) | 2013-12-25 | 2021-08-03 | Sapporo Medical University | Anti-trop2 antibody-drug conjugate |
| DK3466976T3 (da) | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | Anti-her2-antistof-lægemiddelkonjugat |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
| CN107406508B (zh) * | 2014-12-04 | 2022-04-05 | 地中海治疗诊断有限公司 | 人源化的抗trop-2单克隆抗体及其应用 |
| IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
| CN104974988B (zh) * | 2015-07-31 | 2016-08-24 | 南京麦科林生物医药科技有限公司 | 抗胰腺癌单克隆抗体及其应用 |
| US11739163B2 (en) * | 2016-09-29 | 2023-08-29 | Aebi Ltd. | Therapeutic multi-targeting constructs and uses thereof |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| WO2018135501A1 (ja) | 2017-01-17 | 2018-07-26 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体－薬物コンジュゲート |
| TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| KR102630307B1 (ko) | 2017-08-31 | 2024-01-29 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
| CA3073924C (en) | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| JP7403444B2 (ja) | 2017-10-20 | 2023-12-22 | エフ． ホフマン－ラ ロシュ アーゲー | 抗体の複写保護措置 |
| CA3100608A1 (en) | 2018-05-18 | 2019-11-21 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
| JP7481255B2 (ja) | 2018-08-23 | 2024-05-10 | 第一三共株式会社 | 抗体薬物複合体の感受性マーカー |
| WO2020094670A1 (en) | 2018-11-05 | 2020-05-14 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CN112243443B (zh) * | 2019-05-10 | 2023-03-17 | 江苏豪森药业集团有限公司 | 抗trop-2抗体、其抗原结合片段及其医药用途 |
| SG11202112429PA (en) | 2019-05-29 | 2021-12-30 | Daiichi Sankyo Co Ltd | Dosage of an antibody-drug conjugate |
| WO2021027851A1 (zh) * | 2019-08-12 | 2021-02-18 | 凯惠科技发展(上海)有限公司 | 一种trop2抗体及其制备方法、其偶联物和应用 |
| CA3176626A1 (en) | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| CA3186059A1 (en) | 2020-08-13 | 2022-02-17 | Romas Kudirka | Pyrazoloazepine immunoconjugates, and uses thereof |
| KR20230163450A (ko) | 2021-03-26 | 2023-11-30 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 2-아미노-4-카복사마이드-벤즈아제핀 면역접합체 및 이의 용도 |
| TW202304520A (zh) | 2021-03-26 | 2023-02-01 | 美商博特生物治療公司 | ２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途 |
| WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Antibodies masked in protease-wells |
| WO2023180485A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2219699T3 (es) * | 1995-10-19 | 2004-12-01 | Bristol-Myers Squibb Company | Anticuerpo monoclonal br110 y usos del mismo. |
| IL163852A0 (en) * | 2002-03-01 | 2005-12-18 | Immunomedics Inc | Rs7 antibodies |
| US7420041B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2007095745A1 (en) * | 2006-02-24 | 2007-08-30 | Arius Research Inc. | Cancerous disease modifying antibody 141205-02 |
-
2007
- 2007-05-30 US US11/807,837 patent/US20080131428A1/en not_active Abandoned
-
2008
- 2008-05-23 AU AU2008255528A patent/AU2008255528A1/en not_active Abandoned
- 2008-05-23 CA CA002687586A patent/CA2687586A1/en not_active Withdrawn
- 2008-05-23 WO PCT/CA2008/000979 patent/WO2008144891A1/en active Application Filing
- 2008-05-23 CN CN200880017614A patent/CN101679526A/zh active Pending
- 2008-05-23 JP JP2010509640A patent/JP2010528056A/ja not_active Withdrawn
- 2008-05-23 EP EP08757121A patent/EP2155791A4/en not_active Withdrawn
- 2008-05-23 MX MX2009012732A patent/MX2009012732A/es not_active Application Discontinuation
- 2008-05-23 KR KR1020097024842A patent/KR20100003366A/ko not_active Application Discontinuation
-
2009
- 2009-11-12 IL IL202092A patent/IL202092A0/en unknown
- 2009-11-24 CR CR11127A patent/CR11127A/es not_active Application Discontinuation
- 2009-11-24 MA MA32371A patent/MA31393B1/fr unknown
- 2009-11-25 ZA ZA200908346A patent/ZA200908346B/xx unknown
- 2009-11-26 CO CO09135218A patent/CO6140062A2/es unknown
- 2009-11-27 EC EC2009009770A patent/ECSP099770A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA31393B1 (fr) | 2010-05-03 |
| CR11127A (es) | 2009-12-29 |
| EP2155791A4 (en) | 2010-09-22 |
| IL202092A0 (en) | 2010-06-16 |
| EP2155791A1 (en) | 2010-02-24 |
| ECSP099770A (es) | 2009-12-28 |
| KR20100003366A (ko) | 2010-01-08 |
| ZA200908346B (en) | 2010-08-25 |
| WO2008144891A1 (en) | 2008-12-04 |
| US20080131428A1 (en) | 2008-06-05 |
| MX2009012732A (es) | 2009-12-10 |
| CN101679526A (zh) | 2010-03-24 |
| JP2010528056A (ja) | 2010-08-19 |
| AU2008255528A1 (en) | 2008-12-04 |
| CA2687586A1 (en) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6140062A2 (es) | Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas | |
| CO6241160A2 (es) | Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer | |
| CO2022013599A2 (es) | Anticuerpos anti-ccr8 para el tratamiento del cáncer | |
| CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
| JP2016116536A5 (es) | ||
| JP2013517487A5 (es) | ||
| MX2021014094A (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso. | |
| ECSP12012138A (es) | Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| AR054254A1 (es) | Terapia adyuvante con trastuzumab (herceptin registrado) | |
| AR050642A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| De Lorenzo et al. | Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine | |
| SI2631248T1 (en) | Treatment of tumors using a specific antibody to L1 | |
| RU2009131840A (ru) | Антитела, модифицирующие раковые заболевания | |
| MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
| Wang et al. | A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models | |
| AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer | |
| RU2009104624A (ru) | Антитела, модифицирующие раковые заболевания | |
| RU2009131838A (ru) | Антитела, модифицирующие раковые заболевания | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| MX2009001014A (es) | Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie. | |
| PE20091406A1 (es) | Anticuerpos modificadores de enfermedades cancerosas | |
| JP6207531B2 (ja) | 放射線感受性を調節するためのｈｅｒ３阻害剤 | |
| PE20091902A1 (es) | Anticuerpos modificadores de enfermedades cancerosas |